目的 探讨金水宝胶囊联合丙酸倍氯米松治疗支气管哮喘的有效性和安全性。方法 选取2016年4月-2017年4月哈尔滨医科大学附属第二医院收治的支气管哮喘患者149例，随机分成对照组（74例）和治疗组（75例）两组。对照组患者吸入丙酸倍氯米松气雾剂，50 μg/次，15~20 min内吸入完毕，3次/d。治疗组患者在对照组基础上口服金水宝胶囊，3次/粒，3次/d。两组患者均治疗2周。观察两组患者临床疗效，同时比较治疗前后两组患者肺功能、炎症因子水平和哮喘控制测试评分（ACT）评分。结果 治疗后，对照组和治疗组临床总有效率分别为85.14%和96.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者一秒用力呼气容积（FEV₁）、最大呼气流量（PEF）、肺活量（VC）指标水平均显著升高（P<0.05），且治疗组患者上述肺功能明显高于对照组（P<0.05）。治疗后，两组患者白细胞介素-4（IL-4）和肿瘤坏死因子-α（TNF-α）水平显著降低（P<0.05），γ-干扰素（IFN-γ）显著升高（P<0.05），同时治疗后治疗组上述炎症因子水平明显优于对照组（P<0.05）。治疗后，两组患者ACT评分均显著升高（P<0.05），且治疗后治疗组ACT评分明显高于对照组（P<0.05）。结论 金水宝胶囊联合丙酸倍氯米松治疗支气管哮喘疗效好，肺功能改善明显，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy and safety of Jinshuibao Capsules combined with beclomethasone dipropionate in treatment of bronchial asthma. Methods Patients (149 cases) with bronchial asthma in the 2nd Affiliated Hospital of Harbin Medical University from April 2016 to April 2017 were randomly divided into control (74 cases) and treatment (75 cases) groups. Patients in the control group were inhalation administered with Beclometasone Dipropionate Aerosol, 50 μg/time for 15-20 min, three times daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the lung function, the inflammatory factor levels, ACT scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 85.14% and 96.00% respectively, and there were differences between two groups (P<0.05). After treatment, the FEV1, PEF, and VC levels in two groups were significantly increased (P<0.05), and the lung function in the treatment group after treatment was significantly higher than that in the control group (P<0.05). After treatment, the IL-4 and TNF-α levels in two groups were significantly decreased (P<0.05), but IFN-γ levels were significantly increased (P<0.05), and the inflammatory factor levels in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the ACT scores in two groups were significantly increased (P<0.05), and the ACT scores in the treatment group after treatment were significantly higher than those in the control group (P<0.05). Conclusion Jinshuibao Capsules combined with beclomethasone dipropionate in treatment of bronchial asthma has good curative effect on bronchial asthma, can obviously improve the lung function, which has a certain clinical application value.